Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2019 09/17/2019 09/18/2019 09/19/2019 09/20/2019 Date
236.12(c) 238.7(c) 235.17(c) 235.62(c) 238.79(c) Last
1 598 424 1 220 071 1 578 160 1 260 814 3 558 728 Volume
-0.22% +1.09% -1.48% +0.19% +1.35% Change
More quotes
Financials (USD)
Sales 2019 14 128 M
EBIT 2019 7 418 M
Net income 2019 5 724 M
Finance 2019 482 M
Yield 2019 -
Sales 2020 13 898 M
EBIT 2020 7 121 M
Net income 2020 5 450 M
Finance 2020 4 607 M
Yield 2020 -
P/E ratio 2019 7,87x
P/E ratio 2020 7,90x
EV / Sales2019 3,08x
EV / Sales2020 2,84x
Capitalization 44 044 M
More Financials
Company
Biogen is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (84.4%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; -... 
Sector
Pharmaceuticals
Calendar
10/02Presentation
More about the company
Surperformance© ratings of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC.
09/18BIOGEN : to Study Higher Dose of Spinraza in Spinal Muscular Atrophy
DJ
09/18Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Stud..
GL
09/17Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Inde..
GL
09/16BIOGEN : Eisai and biogen to discontinue phase iii clinical studies of bace inhi..
AQ
09/13BIOGEN : New Research Demonstrate Biogen's Continued Commitment to Improve Care ..
AQ
09/13BIOGEN : Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhi..
PR
09/12BIOGEN : to Report Secondary Quarter 2019 Financials October 22,2019
AQ
09/12BIOGEN INC. : - New Data Presented at ECTRIMS Reinforce Long-term Benefits of TE..
AQ
09/12New Research Demonstrate Biogen's Continued Commitment to Improve Care of Pat..
GL
09/11BIOGEN : New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA..
AQ
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Sector news : Biopharmaceuticals
03:12aWalmart Set to Stop Sales of E-Cigarettes -- WSJ
DJ
09/20DR REDDY LABORATORIES : . Reddy's Suspends Shipments of Ranitidine
DJ
09/20ALLERGAN : Form 8.3 -
DJ
09/20NOVO NORDISK : FDA Approves Novo Nordisk's Rybelsus Diabetes Tablets
DJ
09/20ZOETIS : Says EC Grants Marketing Authorization for Antiparasitic Medication for..
DJ
More sector news : Biopharmaceuticals
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 260,20  $
Last Close Price 238,79  $
Spread / Highest target 47,8%
Spread / Average Target 8,97%
Spread / Lowest Target -15,0%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-20.65%44 044
CSL LIMITED26.65%72 057
ALEXION PHARMACEUTICALS8.54%23 840
SAMSUNG BIOLOGICS CO LTD--.--%18 831
GRIFOLS15.63%17 700
BIOMARIN PHARMACEUTICAL INC.-11.98%13 451